Novo Nordisk Slashes India Obesity Drug Price, Eyes 7x Uptake

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Novo Nordisk Slashes India Obesity Drug Price, Eyes 7x Uptake
Overview

Novo Nordisk India has dramatically reduced prices for its blockbuster obesity therapy Wegovy by up to 37%. The company anticipates this move could boost patient uptake five-to-seven-fold, mirroring its prior success with insulin price cuts. This strategy aims to capture significant market share ahead of anticipated generic competition from rivals like Eli Lilly and others, positioning Novo Nordisk for substantial growth in India's rapidly expanding obesity treatment market.

Price Cut Aims for Wider Access

Novo Nordisk India expects its obesity therapy market to evolve rapidly following a significant price reduction for its injectable semaglutide treatment, Wegovy. Managing Director Vikrant Shrotriya stated the company foresees patient uptake potentially increasing five-to-seven-fold, drawing a parallel to their experience with insulin price cuts in 2020. This strategic decision is aimed at improving patient access rather than solely reacting to the threat of generics.

Generics Loom as Market Heats Up

The Indian market for obesity treatments is experiencing swift expansion, attracting global attention. Eli Lilly & Company is another major player eyeing a substantial share. Analysts project that with the patent expiry of semaglutide in India in March, an incremental opportunity worth Rs 5,000 crore for generic versions could emerge globally and domestically over the next 12 to 15 months. This competitive pressure underscores Novo Nordisk's proactive pricing strategy.

Significant Revenue Potential Ahead

For the fiscal year 2027, analysts estimate an incremental revenue opportunity of Rs 1,000 to Rs 2,000 crore within India's branded formulation space. Novo Nordisk, a pioneer and dominant player in insulin analogues worldwide, launched its obesity and diabetes therapies, including Wegovy and Ozempic, in India last year. The company slashed Wegovy's price by up to 37% in November last year from its launch price to gain ground in this burgeoning market.

Novo Nordisk's India Strategy

Shrotriya anticipates a competitive market evolution, likening it to AI adoption, where multiple players will emerge, ultimately benefiting patients through improved access and services. Novo Nordisk's focus remains on being the preferred partner for doctors and patients by emphasizing quality, reliability, and education. The company also plans to expand its portfolio, with U.S. Food and Drug Administration approving oral semaglutide in December 2025, which is slated for a U.S. launch soon, with India's launch dependent on global uptake and production capacity. Novo Nordisk has a long-standing presence in India, boasting the country's largest diabetes care franchise.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.